Sanoculis

Company Overview

Snapshot

Founded in February 2012 by Nir Israeli, Vadim Shmukler, and Dr. Yoseph Glovinsky, Sanoculis operates with 1–10 employees. The company has raised $18.5M across 3 funding rounds from 6 investors. In April 2025, Sanoculis received CE Mark approval for its MINT product, designed for glaucoma treatment.

Business overview

Sanoculis is a Health Tech & Life Sciences company specializing in medical devices for ophthalmic treatments. The company develops a Minimally Invasive Micro Sclerostomy (MIMS) solution, which includes a sterile tool and a multi-use external machine, to create a sclero-corneal drainage channel for reducing intraocular pressure in glaucoma patients. Its technology utilizes a cutting and drilling device to minimize tissue trauma and scar formation, ensuring controlled fluid flow. Sanoculis operates within the Medical Treatment & Therapeutics sector, serving healthcare providers, hospitals, surgeons, and clinics in markets such as India, China, and Europe.

Strategic signal

In April 2025, Sanoculis secured CE Mark approval for its MINT product, a significant regulatory milestone for its glaucoma treatment device. This approval validates the device's safety and performance within the European market, signaling strong commercial potential and market readiness for investors and innovation teams in the ophthalmology sector. It positions Sanoculis to expand its reach and address unmet needs in glaucoma care with a new, approved solution.

Company Intelligence Q&A

What is Sanoculis's core product?

Sanoculis's core product is the Minimally Invasive Micro Sclerostomy (MIMS) solution, a microfluidic full-thickness procedure designed to treat glaucoma by creating a sclero-corneal drainage channel to reduce intraocular pressure.

When did Sanoculis receive CE Mark approval for its MIMS device?

In March 2017, Sanoculis was granted CE marking for its MIMS device and procedure, indicating compliance with European health, safety, and environmental protection standards.

What strategic agreements did Sanoculis announce in July 2022?

In July 2022, Sanoculis announced strategic agreements with Bausch + Lomb aimed at addressing unmet needs in glaucoma treatment, signaling a significant partnership in the ophthalmic industry.

Which investors participated in Sanoculis's equity investment in January 2023?

In January 2023, Eckuity joined Bausch + Lomb in an equity investment in Sanoculis, contributing to the company's funding efforts.

When did Sanoculis receive CE Mark approval for its MINT product?

In April 2025, Sanoculis received CE Mark approval for its MINT product, which is designed for the treatment of glaucoma.